Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival
Authors:
- 24 January 2025
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 379, 558-573
Abstract
No abstract availableKeywords
Funding Information
- Coordination of Higher Education Personnel Improvement (88887.506690/2020-00)
- Minas Gerais State Foundation of Support to the Research (APQ-02618-23, RED-00028-23, 25036, RED-00202-22, APQ-04650-23, TEC-RED-00282-16, APQ-00730-23)
- Ulsan National Institute of Science and Technology
- National Council for Scientific and Technological Development (406792/2022-4, 306198/2021-5, 442731/2020-5, 465425/2014-3)
- Ministério da Ciência, Tecnologia e Inovação
This publication has 53 references indexed in Scilit:
- Remdesivir for the Treatment of COVID-19: A Narrative ReviewInfectious Diseases and Therapy, 2024
- Remdesivir: A Review in COVID-19Drugs, 2023
- What is really ‘Long COVID’?Inflammopharmacology, 2023
- Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factorsJournal of Pharmaceutical Investigation, 2022
- Intranasal drug delivery: opportunities and toxicologic challenges during drug developmentDrug Delivery and Translational Research, 2021
- Acetylcysteine for the Treatment of Suspected Remdesivir‐Associated Acute Liver Failure in COVID‐19: A Case SeriesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Liver injury in remdesivir-treated COVID-19 patientsHepatology International, 2020
- CNS penetration of potential anti-COVID-19 drugsJournal of Neurology, 2020
- Enhanced Antiviral Activity of Acyclovir Loaded into Nanoparticles2012
- Sterically stabilized liposome therapeuticsAdvanced Drug Delivery Reviews, 1995